

## Aarey Drugs & Pharmaceuticals Ltd Q1 FY20 conference call to be organized on Tuesday, 27th August, 2019 at 4.00 pm IST.

Aarey Drugs & Pharmaceuticals Ltd, one of the API & Bulk Drugs manufacturer will be hosting a conference call for investors and analysts on Tuesday, 27th August, 2019 at 4.00 pm IST for the discussion of Q1FY 20 results ended 30th June, 2019.

The call will be initiated with a brief management discussion on the business and earnings performance followed by an interactive question and answer session.

The management team will be represented by:

Mr. Mihir Ghatalia , Managing Director, Mr. Rajesh Ghatalia, Chief Financial Officer

## Tuesday, 27th August, 2019 - 4.00 pm IST

Conference Dial-In Numbers	
Mumbai (Primary No.)	+91 22 6280 1239
All India (local)	+91-70456 71221
USA	18667462133
UK	08081011573
Singapore	8001012045
Hong Kong	800964448

## About Aarey Drugs & Pharmaceuticals Ltd. -

Aarey Drugs & Pharmaceuticals Limited, (BSE 524412), is engaged in API/Bulk Drugs manufacturing and offers a range of products for various industrial applications, it is also engaged in trading of various chemicals. Its products include Monomethyl Urea (MMU, Dimethyl Urea (DMU), Metphormin, Mefanamic acid, and Doxaphylline. Its other businesses include trading aromatics chemical, chemical acid, chlor alkalis, industrial alcohols, industrial ketones, glycols and glycol ethers, fibre intermediates, industrial amines, acetates and esters, chlorinated solvents, industrial intermediates and industrial chemicals. *After a long hiatus it is reinvesting in its manufacturing business.* 

For further information please contact:

Sonal Kumar Shrivastava (M) 9324748334 sonalkumar@kirinadvisors.com

Statements during this call relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.